Protein for Osteoarthritis and Asthma is under clinical development by Translational Biosciences and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Protein for Osteoarthritis and Asthma’s likelihood of approval (LoA) and phase transition for Asthma took place on 15 Feb 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Protein for Osteoarthritis and Asthma Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Protein for Osteoarthritis and Asthma overview

Protein (allogenic mesenchymal trophic factors) is under development for the treatment of asthma. It is administered through intraarticular, intranasal, intravenous and subcutaneous route. It is derived from human umbilical cord tissue-derived mesenchymal stem cells (UC-MSC). It was also under development for the treatment of osteoarthritis.

Quick View Protein for Osteoarthritis and Asthma LOA Data

Report Segments
  • Innovator
Drug Name
  • Protein for Osteoarthritis and Asthma
Administration Pathway
  • Intraarticular
  • Intravenous
  • Nasal
  • Subcutaneous
Therapeutic Areas
  • Musculoskeletal Disorders
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.